CRISPR Therapeutics Aktie
45,20
EUR
-3,40
EUR
-7,00
%
47,89
USD
+0,05
USD
+0,10
%
Werbung
CRISPR Therapeutics Aktie Analyse
26.07.19 | CRISPR Therapeutics Buy | Canaccord Adams | |
30.11.18 | CRISPR Therapeutics Buy | Needham & Company, LLC | |
15.05.18 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
28.03.17 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
14.11.16 | CRISPR Therapeutics overweight | Barclays Capital |
Werbung
Werbung